Alnylam Pharmaceuticals, Inc. vs Ralph Lauren Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Ralph Lauren Corp trades at $397.75 (market cap $23.70B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.94% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RL | |
|---|---|---|
Market Cap | $29.60B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $414.25 |
52-Week Low | $205.48 | $285.35 |
Enterprise Value | $27.56B | $24.76B |
Dividend Yield | — | 0.94% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →